Huatai Zijin Investment

Huatai Zijin Investment is a private equity firm based in Nanjing, Jiangsu, China, established in 1991. The firm focuses on investing in innovative high-tech companies, particularly in the biotechnology and healthcare sectors. It has a history of making investments in life science and medical technology companies.

The firm's investment strategy includes participating in early-stage, growth, late-stage, pre-IPO, and buyout investments. Huatai Zijin Investment has been involved in various sectors, including biotechnology, healthcare, medical devices, pharmaceuticals, electronics, dental, manufacturing, and health diagnostics. Its geographical focus includes China and the United States.

Huatai Zijin Investment has a track record of investing in companies such as Sanyou Biopharmaceuticals, Rino.ai, Xiushi Biopharmaceuticals, and Ab&B Biotech. The firm typically invests in rounds with 1-2 participants, with an average round size of $46 million. It has made a total of 38 investments, with an average of 1.15 rounds per year, and has led 8 investments. The firm has also had 3 exits. Notable limited partners include Zhangyue Technology, Ourpalm, and Jiangsu King's Luck Brewery Joint-Stock. The firm's investment philosophy emphasizes supporting innovative companies in the biotechnology and healthcare sectors to drive growth and development in these industries.